Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy
Abstract Introduction Adoptive cellular therapy with tumor‐infiltrating lymphocytes (TIL) has demonstrated promising clinical benefits in several solid tumors, but the efficacy of this therapy might be compromised by the “prone‐to‐exhaustion” phenotype of TIL and poor persistence in vivo. This calls...
Saved in:
| Main Authors: | Hao Feng, Ling Qiu, Zixiao Shi, Yao Sheng, Peipei Zhao, Di Zhou, Fei Li, Hailin Yu, Yanan You, Hui Wang, Ming Li, Shurong Zhu, Yan Du, Jun Cui, Jingwei Sun, Yarong Liu, Hua Jiang, Xin Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The inhibitory effect of tyrosine kinase inhibitors on angiogenesis in zebrafish and interrelationship with the activation of the PI3K/AKT pathway
by: Lili Yang, et al.
Published: (2025-08-01) -
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
by: Wei Zhang, et al.
Published: (2025-05-01) -
Histopathological biomarkers in squamous cell carcinoma of the vulva: the prognostic relevance of tumor-infiltrating lymphocytes (TILs)—a retrospective study of 157 cases
by: Gilbert Georg Klamminger, et al.
Published: (2025-04-01) -
Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)
by: The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, et al.
Published: (2025-06-01) -
Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway
by: Adrish Sen, et al.
Published: (2025-01-01)